[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise Vera Scots-Knight Ph.D.", "age": 65, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 950947, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Edward Sermon", "age": 55, "title": "Co-Founder, General Counsel, Business Development & Company Secretary", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 668869, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A.", "age": 67, "title": "Co-Founder & Chief Business Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 66, "title": "Senior VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 53, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 59, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kara", "title": "Senior VP and Head of Pharmaceutical Development & CMC", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.13, "dayLow": 2.05, "dayHigh": 2.335, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.13, "regularMarketDayLow": 2.05, "regularMarketDayHigh": 2.335, "payoutRatio": 0.0, "beta": 0.654, "forwardPE": -76.666664, "volume": 2258174, "regularMarketVolume": 2258174, "averageVolume": 1357567, "averageVolume10days": 2029750, "averageDailyVolume10Day": 2029750, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 365700000, "fiftyTwoWeekLow": 1.575, "fiftyTwoWeekHigh": 5.02, "fiftyDayAverage": 2.4592, "twoHundredDayAverage": 3.5432, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1765130368, "profitMargins": 0.0, "floatShares": 471674357, "sharesOutstanding": 159000000, "sharesShort": 6544993, "sharesShortPriorMonth": 6360249, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.041199997, "heldPercentInsiders": 0.00992, "heldPercentInstitutions": 0.75041, "shortRatio": 4.99, "shortPercentOfFloat": 0.048499998, "impliedSharesOutstanding": 140243008, "bookValue": 0.393, "priceToBook": 5.852417, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -43253000, "trailingEps": -0.3, "forwardEps": -0.03, "enterpriseToEbitda": -39.109, "52WeekChange": -0.17562723, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 2.3, "targetHighPrice": 10.311678, "targetLowPrice": 6.1577535, "targetMeanPrice": 7.7330933, "targetMedianPrice": 7.248757, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 69802000, "totalCashPerShare": 0.088, "ebitda": -45134000, "totalDebt": 6429000, "quickRatio": 5.242, "currentRatio": 5.399, "debtToEquity": 10.545, "returnOnAssets": -0.39992002, "returnOnEquity": -0.7758, "freeCashflow": -21499124, "operatingCashflow": -32834000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MREO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1556112600000, "shortName": "Mereo BioPharma Group plc", "fiftyTwoWeekLowChangePercent": 0.46031737, "fiftyTwoWeekRange": "1.575 - 5.02", "fiftyTwoWeekHighChange": -2.72, "fiftyTwoWeekHighChangePercent": -0.5418327, "fiftyTwoWeekChangePercent": -17.562723, "earningsTimestamp": 1742988636, "earningsTimestampStart": 1742988636, "earningsTimestampEnd": 1742988636, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.3, "epsForward": -0.03, "epsCurrentYear": -0.03857, "priceEpsCurrentYear": -59.631836, "fiftyDayAverageChange": -0.15919995, "fiftyDayAverageChangePercent": -0.064736485, "twoHundredDayAverageChange": -1.2432001, "twoHundredDayAverageChangePercent": -0.3508693, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1744934069, "regularMarketTime": 1744920001, "exchange": "NCM", "messageBoardId": "finmb_307970474", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 7.9812126, "regularMarketPrice": 2.3, "longName": "Mereo BioPharma Group plc", "postMarketChangePercent": 5.2174, "postMarketPrice": 2.42, "postMarketChange": 0.12, "regularMarketChange": 0.16999984, "regularMarketDayRange": "2.05 - 2.335", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1357567, "fiftyTwoWeekLowChange": 0.7249999, "marketState": "CLOSED", "displayName": "Mereo BioPharma", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]